Roche Warns On Anti-Trust Zeal While Posting Painful Q1
But Says Biosimilar Erosion ‘Has Already Hit High Watermark’
Biosimilar erosion and slack drugs sales caused by the pandemic depressed Roche’s first quarter pharma revenue while its diagnostics unit saw sales soar on COVID testing.
